- 11.16.2023
- Updates
CBS News: U.S. military veterans turn to psychedelics in Mexico for PTSD treatment
Suicide rates for American service members and veterans are nothing short of catastrophic, with recent estimates claiming almost 17 vets take their own lives in the U.S. every day. Many of them suffer from post-traumatic stress and debilitating brain injuries, which traditional medications have largely failed to cure.
- 11.16.2023
- Updates
Stars and Stripes: Ecstasy and magic mushrooms show signs of helping with PTSD treatment, researchers say
Researchers and veterans testifying Tuesday on the use of psychedelic drugs to relieve post-traumatic stress disorder and suicidal thoughts urged House lawmakers to back more studies into the alternative treatments.
- 11.8.2023
- Updates
Newsweek: The Case for Ibogaine: Kentucky's Opportunity to Lead in the Fight Against Opioid Addiction | Opinion
As the opioid epidemic continues to grip our nation, claiming lives, destroying families, and burdening communities, it is imperative that we explore every viable solution. Among these potential solutions is a powerful, natural, non-addictive substance known as ibogaine. As voices that have served in political and military capacities, we unite in our appeal to the Kentucky Opioid Abatement Advisory Commission (KYOAAC): Allocate $42 million for ibogaine research. Kentucky has a unique chance to pioneer a revolutionary approach to combat opioid addiction and pave the way for the entire country.
- 11.3.2023
- Updates
Lucid News: An Ambitious Vision Drives Kentucky’s Ibogaine Plan to Treat Opioid Dependency
When Bryan Hubbard was appointed Executive Director of the newly formed Kentucky Opioid Abatement Advisory Commission in 2021, he had already been tracking psychedelic-assisted therapies in the media for three years.
Marijuana Moment: Veteran Access To Psychedelics Requires Balance Of Speed And Caution, Says Panel With VA And Former CDC Officials
Experts and advocates—including a Department of Veterans Affairs (VA) official and a former director of the Centers for Disease Control and Prevention (CDC)—recently convened for a Harvard University panel to discuss efforts to expand veteran access to psychedelic-assisted therapy.